Occidental Petroleum, Merus shares rise premarket; MoonLake slumps

Genmab's recent decision to acquire Merus for $8 billion in an all-cash deal marks a significant move in the biotech sector. This acquisition not only strengthens Genmab's portfolio but also highlights the growing trend of consolidation in the pharmaceutical industry. By bringing Merus's innovative therapies under its wing, Genmab aims to enhance its research capabilities and expand its market reach, which could lead to groundbreaking advancements in cancer treatment.

Genmab is reportedly in advanced discussions to acquire the Dutch drugmaker Merus, a move that could significantly enhance its portfolio in the biopharmaceutical sector. This acquisition is important as it reflects Genmab's strategy to expand its capabilities and offerings in innovative therapies, potentially leading to new treatments for patients and strengthening its position in the competitive market.

Genmab A/S, a leading Danish biotechnology company, is reportedly close to finalizing a deal to acquire Merus NV, a Dutch firm focused on developing innovative treatments for head and neck cancer. This acquisition could significantly enhance Genmab's portfolio and strengthen its position in the oncology market, which is crucial as the demand for effective cancer therapies continues to rise.

Occidental Petroleum is currently in discussions to sell its OxyChem unit for approximately $10 billion. This deal is significant as it would separate one of the largest standalone petrochemical units globally, potentially allowing Occidental to focus on its core operations while providing a substantial financial boost. Such a move could reshape the petrochemical landscape and enhance market competition.

MoonLake has released its findings from the Phase 3 trials for hidradenitis suppurativa, showing a mix of outcomes. While some results were promising, others fell short of expectations. This matters because it highlights the ongoing challenges in developing effective treatments for this chronic skin condition, affecting many individuals worldwide.

President Trump has reignited his threat to impose 100% tariffs on movies not made in the United States, claiming that the American film-making industry has been 'stolen' by foreign countries. This move could have significant implications for the film industry, potentially raising costs for consumers and affecting international collaborations.

Ormat Technologies has reached a significant milestone as its stock price hit a 52-week high of 95.39 USD. This achievement reflects the company's strong performance and investor confidence in its renewable energy solutions. As the demand for sustainable energy sources continues to grow, Ormat's success is a positive indicator for the industry and could attract more investors looking for opportunities in green technology.

The Trump administration has implemented stricter export controls targeting Chinese companies, particularly affecting subsidiaries of entities that have been blacklisted by the US government. This move is significant as it reflects ongoing tensions between the US and China, impacting trade relations and potentially hindering the operations of affected companies. The tightening of these controls could lead to further economic repercussions and escalate the trade conflict.

In a recent interview, Honeywell's Energy and Sustainability Solutions President & CEO Ken West emphasized the growing demand for energy, predicting that the world will require more power in the future. This insight is crucial as it highlights the need for innovative solutions and sustainable practices to meet increasing energy needs, making it a significant topic for businesses and policymakers alike.

Carnival Corporation has reported a record profit of $2 billion for the third quarter of 2025, marking a significant milestone for the cruise line industry. This impressive financial performance not only highlights the company's recovery post-pandemic but also reflects strong consumer demand for travel experiences. Additionally, Carnival raised its guidance for the upcoming quarters, indicating confidence in sustained growth. This news is crucial as it signals a robust rebound in tourism and could positively impact related sectors.

CorVel Corp's stock has reached a 52-week low, dropping to $77.64, which raises concerns among investors about the company's financial health and market performance. This decline could impact investor confidence and may lead to further scrutiny of CorVel's business strategies and future prospects.